The discovery and classification of 16 supernovae at high redshifts in ELAIS-S1 - the Stockholm VIMOS Supernova Survey II

Supernova surveys can be used to study a variety of subjects such as: (i) cosmology through type Ia supernovae (SNe), (ii) star-formation rates through core-collapse SNe, and (iii) supernova properties and their connection to host galaxy characteristics. The Stockholm VIMOS Supernova Survey (SVISS) is a multi-band imaging survey aiming to detect supernovae at redshift ~0.5 and derive thermonuclear and core-collapse supernova rates at high redshift. In this paper we present the supernovae discovered in the survey along with light curves and a photometric classification into thermonuclear and core-collapse types. To detect the supernovae in the VLT/VIMOS multi-epoch images, we used difference imaging and a combination of automatic and manual source detection to minimise the number of spurious detections. Photometry for the found variable sources was obtained and careful simulations were made to estimate correct errors. The light curves were typed using a Bayesian probability method and Monte Carlo simulations were used to study misclassification. We detected 16 supernovae, nine of which had a core-collapse origin and seven had a thermonuclear origin. The estimated misclassification errors are quite small, in the order of 5%, but vary with both redshift and type. The mean redshift of the supernovae is 0.58. Additionally, we found a variable source with a very extended light curve that could possibly be a pair instability supernova.Comment: 30 pages, 15 figures, Accepted for publication in A&A. Version with high resolution images available at: http://www.astro.su.se/~jens/sviss_sne.pd

The GMOX science case: resolving galaxies through cosmic time

We present the key scientific questions that can be addressed by GMOX, a Multi-Object Spectrograph selected for feasibility study as a 4th generation instrument for the Gemini telescopes. Using commercial digital micro-mirror devices (DMDs) as slit selection mechanisms, GMOX can observe hundreds of sources at R∼5000 between the U and K band simultaneously. Exploiting the narrow PSF delivered by the Gemini South GeMS MCAO module, GMOX can synthesize slits as small as 40mas reaching extremely faint magnitude limits, and thus enabling a plethora of applications and innovative science. Our main scientific driver in developing GMOX has been Resolving galaxies through cosmic time: GMOX 40mas slit (at GeMS) corresponds to 300 pc at z ∼ 1:5, where the angular diameter distance reaches its maximum, and therefore to even smaller linear scales at any other redshift. This means that GMOX can take spectra of regions smaller than 300 pc in the whole observable Universe, allowing to probe the growth and evolution of galaxies with unprecedented detail. GMOXs multi-object capability and high angular resolution enable efficient studies of crowded fields, such as globular clusters, the Milky Way bulge, the Magellanic Clouds, Local Group galaxies and galaxy clusters. The wide-band simultaneous coverage and the very fast slit configuration mechanisms also make GMOX ideal for follow-up of LSST transients

Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

Precise molecular characterization of circulating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) is hampered by their mixed composition of mature and immature cells and lack of specific markers. Here, we focus on mature CD66b+CD10+CD16+CD11b+ PMN-MDSCs (mPMN-MDSCs) from either cancer patients or healthy donors receiving G-CSF for stem cell mobilization (GDs). By RNA sequencing (RNA-seq) experiments, we report the identification of a distinct gene signature shared by the different mPMN-MDSC populations under investigation, also validated in mPMN-MDSCs from GDs and tumor-associated neutrophils (TANs) by single-cell RNA-seq (scRNA-seq) experiments. Analysis of such a gene signature uncovers a specific transcriptional program associated with mPMN-MDSC differentiation and allows us to identify that, in patients with either solid or hematologic tumors and in GDs, CD52, CD84, and prostaglandin E receptor 2 (PTGER2) represent potential mPMN-MDSC-associated markers. Altogether, our findings indicate that mature PMN-MDSCs distinctively undergo specific reprogramming during differentiation and lay the groundwork for selective immunomonitoring, and eventually targeting, of mature PMN-MDSCs

The role of neutrophil gelatinase-associated lipocalin (NGAL) in cerebrospinal fluids for screening of acute bacterial meningitis

Acute bacterial meningitis is a rare but extremely severe disease. The aim of this study was to investigate whether neutrophil gelatinase-associated lipocalin (NGAL) is present and measurable in cerebrospinal fluid (CSF) and if its assessment may be useful for identifying patients with bacterial meningitis

A Unique Presentation of Bilateral Chorioretinal Atrophy

[no abstract available

Detection of elusive DNA copy-number variations in hereditary disease and cancer through the use of noncoding and off-target sequencing reads.

Copy-number variants (CNVs) play a substantial role in the molecular pathogenesis of hereditary disease and cancer, as well as in normal human interindividual variation. However, they are still rather difficult to identify in mainstream sequencing projects, especially involving exome sequencing, because they often occur in DNA regions that are not targeted for analysis. To overcome this problem, we developed OFF-PEAK, a user-friendly CNV detection tool that builds on a denoising approach and the use of "off-target" DNA reads, which are usually discarded by sequencing pipelines. We benchmarked OFF-PEAK on data from targeted sequencing of 96 cancer samples, as well as 130 exomes of individuals with inherited retinal disease from three different populations. For both sets of data, OFF-PEAK demonstrated excellent performance (>95% sensitivity and >80% specificity vs. experimental validation) in detecting CNVs from in silico data alone, indicating its immediate applicability to molecular diagnosis and genetic research

Meningitis caused by toscana virus is associated with strong antiviral response in the CNS and altered frequency of blood antigen-presenting cells

Toscana virus (TOSV) is a Phlebotomus-transmitted RNA virus and a frequent cause of human meningitis and meningoencephalitis in Southern Europe during the summer season. While evidence for TOSV-related central nervous system (CNS) cases is increasing, little is known about the host defenses against TOSV. We evaluated innate immune response to TOSV by analyzing frequency and activation of blood antigen-presenting cells (APCs) and cytokine levels in plasma and cerebrospinal fluid (CSF) from patients with TOSV neuroinvasive infection and controls. An altered frequency of different blood APC subsets was observed in TOSV-infected patients, with signs of monocytic deactivation. Nevertheless, a proper or even increased responsiveness of toll-like receptor 3 and 7/8 was observed in blood APCs of these patients as compared to healthy controls. Systemic levels of cytokines remained low in TOSV-infected patients, while levels of anti-inflammatory and antiviral mediators were significantly higher in CSF from TOSV-infected patients as compared to patients with other infectious and noninfectious neurological diseases. Thus, the early host response to TOSV appears effective for viral clearance, by proper response to TLR3 and TLR7/8 agonists in peripheral blood and by a strong and selective antiviral and anti-inflammatory response in the CNS

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

BackgroundTocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.MethodsA multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.ResultsIn the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6-24.0, P=0.52) and 22.4% (97.5% CI: 17.2-28.3, P<0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.ConclusionsTocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)